Opthea Ltd., of Melbourne, Australia, said it completed its A$45 million (US$33.7 million) capital raising. Proceeds will enable the acceleration and diversification of the company's clinical development strategy for OPT-302, its VEGF-C/D Trap therapy for wet age-related macular degeneration and diabetic macular edema.